Author(s): Brenner MK, Heslop HE
Abstract Share this page
Abstract Adoptive transfer of T cells specific for antigens expressed on tumor cells is an attractive strategy for producing targeted and long-lived anti-tumor activity. T cell therapies have shown activity in selected clinical applications but broader application is limited by inadequate persistence of transferred T cells and by tumor-evasion strategies. Current research focuses on defining the optimum type of cell for transfer, genetically modifying infused T cells to augment function and overcome tumor evasion strategies and modulating the host environment. Copyright 2010 Elsevier Ltd. All rights reserved.
This article was published in Curr Opin Immunol
and referenced in Journal of Clinical & Cellular Immunology